MedTrace Logo

The State of Sexual Development in Children With Inherited Epidermolysis Bullosa

NCT05033574 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 50

Last updated 2021-09-05

No results posted yet for this study

Summary

The aim of the study is to determine the state of sexual development in patients with inherited epidermolysis bullosa; the study is planned to include boys and girls aged 8 to 18 years with a diagnosis of epidermolysis bullosa simplex, junctional epidermolysis bullosa, Kindler syndrome.

Conditions

  • Dermatologic Disease
  • Epidermolysis Bullosa
  • Epidermolysis Bullosa Simplex
  • Epidermolysis Bullosa Dystrophica
  • Epidermolysis Bullosa, Junctional
  • Kindler Syndrome
  • Puberty Disorders
  • Hormone Disturbance

Interventions

DIAGNOSTIC_TEST

Biochemical study of hormone levels

Biochemical study of the level of follicle-stimulating hormone, luteinizing hormone, estradiol, total testosterone, prolactin, 17-hydroxyprogesterone, dehydroepiandrosterone sulfate, cortisol, insulin, thyroid-stimulating hormone, tetraiodothyronine, thyr

DIAGNOSTIC_TEST

Ultrasound examination

Ultrasound examination of the pelvic organs in girls and the scrotum organs in boys

RADIATION

Radiography of the hands

Determination of bone age using radiography of the hands

BEHAVIORAL

Consultation of a medical psychologist

Consultation with a medical psychologist to determine the patient's psychological condition and level of intelligence

Sponsors & Collaborators

  • National Medical Research Center for Children's Health, Russian Federation

    lead OTHER_GOV

Eligibility

Min Age
8 Years
Max Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-12-08
Primary Completion
2021-12-01
Completion
2023-06-01

Countries

  • Russia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05033574 on ClinicalTrials.gov